Filing Flows › Immunome (IMNM) › Q1 2025 › vs Q1 2024
Immunome (IMNM) Q1 2025 vs Q1 2024 (year over year)
Immunome's revenue rose $1.9M (+184%) from $1.0M in Q1 2024 to $2.9M in Q1 2025.
Immunome, Q1 2025: revenue $2.9M (+184% year over year), net loss $41.6M, operating cash flow −$53.1M. The chart draws each line against Q1 2024, the increases inside each band.
Every line
| Line | Q1 2025 | Q1 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $2.9M | $1.0M | $1.9M | +184% |
| Other income, net | $3.0M | $2.8M | $189K | +7% |
| Net loss | $41.6M | $129M | −$87.9M | -68% |
| Costs & expenses | $47.6M | $133M | −$85.8M | -64% |
| Operating costs | $47.6M | $133M | −$85.8M | -64% |
| Research & development | $36.9M | $15.4M | $21.5M | +140% |
| General & admin | $10.7M | $6.0M | $4.7M | +78% |
| Operating cash sources | $59.4M | $13.5M | $45.9M | +340% |
| Depreciation & amortization | $611K | $157K | $454K | +289% |
| Share-based compensation | $5.7M | $2.2M | $3.5M | +164% |
| Cash used in operations | $53.1M | $11.2M | $41.9M | +375% |
| Net loss absorbed | $41.6M | $129M | −$87.9M | -68% |
| Working capital & other | $17.7M | −$116M | $134M | — |
Questions
How much did Immunome's revenue grow year over year in Q1 2025?
Immunome's revenue rose $1.9M (+184%) from $1.0M in Q1 2024 to $2.9M in Q1 2025.